Brief Summary: This is a multi-center, prospective, open-label, single-arm, observational, feasibility study. The goal of this study is to determine the feasibility of intra-spinal stimulation with optimal paresthesia coverage therapy for chronic pain relief in patients with complex regional pain syndrome type I or causalgia. Up to 20 patients with intractable chronic severe limb pain associated with complex regional pain syndrome (CRPS) will be included in the study. A standard of care trial phase to test a subjects' response to Intraspinal-Optimal Stim therapy will be conducted during a 3 to 10-day period. Patients that obtain 50% or greater pain relief during the trial period will undergo permanent implantation of the device. Primary outcome will evaluate pain response at 3 months of therapy, based on NPRS pain score relative to baseline. Patients will be followed up for 6 months after the start of therapy.
To determine the risk of prolonged opioid use in patients receiving tramadol compared with other short acting opioids. Opioid-naive patients undergoing elective surgery. Risk of persistent opioid use after discharge for patients treated with tramadol alone compared with other short acting opioids, using three commonly used definitions of prolonged opioid use from the literature: additional opioid use (defined as at least one opioid fill 90-180 days after surgery); persistent opioid use (any span of opioid use starting in the 180 days after surgery and lasting ≥90 days); and CONSORT definition (an opioid use episode starting in the 180 days after surgery that spans ≥90 days and includes either ≥10 opioid fills or ≥120 days' supply of opioids).
A novel opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System is as strong as morphine but isn't addictive and causes fewer side effects, according to a new study published in the Journal of Neuroinflammation.
Multiple cranial nerve blocks of the greater and lesser occipital, supraorbital, supratrochlear and auriculotemporal nerves are widely used in the treatment of primary headaches. We present efficacy and safety data for these procedures. In an uncontrolled open-label prospective study, 119 patients with chronic cluster headache, chronic migraine, short lasting unilateral neuralgiform attack disorders, new daily persistent headaches, hemicrania continua and chronic paroxysmal hemicrania were examined.
Medicare recently announced a plan to streamline the process of finding coverage and documentation requirements for applicable services. Currently, documentation requirements appear in various locations and on separate websites requiring physicians and staff to navigate multiple websites for information.
An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue prescription opioids.
Steroid injections, nerve stimulators and spinal fusions were no match for the chronic pain in Tammy Durfee's left side. After a decade searching for relief, a four-hour procedure using focused ultrasound put her pain to rest.
Researchers analyzed 21 randomized studies focusing on the effect of either cognitive behavioral therapy (CBT), to redirect pain-related thoughts and behaviors, or mindfulness-based stress reduction (MBSR), combining yoga and meditation to build awareness and acceptance of moment-to-moment experiences (including pain).
The current meta-analysis aimed to quantify the effectiveness of hypnosis for reducing pain and identify factors that influence efficacy. Six major databases were systematically searched for trials comparing hypnotic inductions with no-intervention control conditions on pain ratings, threshold and tolerance using experimentally-evoked pain models in healthy participants. Random effects meta-analysis found analgesic effects of hypnosis for all pain outcomes.
Non-specific low back pain (LBP) is one of the leading causes of global disability. Multidisciplinary pain treatment (MPT) programs comprising educational, physical, and psychological interventions have shown positive treatment effects on LBP. Nonetheless, such programs are costly and treatment opportunities are often limited to specialized medical centers. mHealth and other digital interventions may be a promising method to successfully support patient self-management in LBP. To address these issues, we investigated the clinical effects of a multidisciplinary mHealth back pain App (Kaia App) in a randomized controlled trial (registered at German Clinical Trials Register under DRKS00016329).
People suffering from a debilitating disease known as chronic fatigue syndrome may soon have something they've been seeking for decades: scientific proof of their ailment. Researchers at the Stanford University School of Medicine have created a blood test that can flag the disease, which currently lacks a standard, reliable diagnostic test.
We compare intranasal ketamine with intranasal placebo in providing pain reduction at 30 minutes when added to usual paramedic care with nitrous oxide. Methods: This was a randomized double-blind study of out-of-hospital patients with acute pain who reported a verbal numeric rating scale (VNRS) pain score greater than or equal to 5. Exclusion criteria were younger than 18 years, known ketamine intolerance, nontraumatic chest pain, altered mental status, pregnancy, and nasal occlusion. Patients received usual paramedic care and were randomized to receive either intranasal ketamine or intranasal saline solution at 0.75 mg/kg.
The Forum on Neuroscience and Nervous System Disorders and Global Forum on Innovation in Health Professional Education hosted a public workshop that discussed the state of evidence on the effectiveness of nonpharmacological treatments and integrative health models for pain management, multimodal approaches, and research gaps and key questions for further research.
Hospital program offers intensive physical and occupational therapy, relaxation techniques, stress-management training, and music and therapeutic art to help manage Amplified Pain Syndrome.
Researchers performed a systematic review to synthesize evidence on prognostic factors for physical functioning after multidisciplinary rehabilitation in patients with chronic musculoskeletal pain and used a tool, QUIPS, which was developed specifically for evaluation of study quality of prognostic studies.
Researchers at Penn State are developing a way to deliver on-demand, guided mindfulness practices via Amazon Alexa to patients experiencing chronic pain. Through their method, a smart assistant will provide Mindfulness-Based Stress Reduction (MBSR) practices to individuals in their homes.
Pain-related diseases are the top leading causes of life disability. Identifying brain regions involved in persistent neuronal changes will provide new insights for developing efficient chronic pain treatment. Here, we showed that anterior nucleus of paraventricular thalamus (PVA) plays an essential role in the development of mechanical hyperalgesia in neuropathic and inflammatory pain models in mice.
Association of American Medical Colleges President and CEO Darrell G. Kirch, MD, issued a statement about the Opioid Workforce Act of 2019 (H.R. 2439), which was introduced in the U.S. House of Representatives and would support new addiction medicine, addiction psychiatry, or pain management residency positions.
Medtronic today announced primary endpoint (3-month) results of the Vectors Post Market Clinical Study that demonstrated effective pain relief and improved function in patients with chronic intractable back and leg pain treated with spinal cord stimulation (SCS) utilizing the EvolveSM workflow
Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.